Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accustem SciencesACUT -28.89%29 EV-to-OCF is -2.18 as of Aug. 25, 2026. GuruFocus rates ACUT with a GF Score™ of 29/100. Among 1,409 Biotechnology companies, Accustem Sciences ranks worse than 57.98% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Accustem Sciences's Enterprise Value is $2.62 Mil.
Accustem Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.21 Mil. Therefore, Accustem Sciences's EV-to-OCF for today is -2.18.
The historical rank and industry rank for Accustem Sciences's EV-to-OCF or its related term are showing as below:
ACUT'
s EV-to-OCF Range Over the Past 10 Years
Min: -2.18 Med: 0 Max: -2.18
Current: -2.18
During the past 4 years, the highest EV-to-OCF of Accustem Sciences was -2.18. The lowest was -2.18. And the median was .
ACUT's EV-to-OCF is ranked worse than 57.98% of 1409
companies
in the Biotechnology industry
Industry Median: -3.68
vs ACUT: -2.18
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Accustem Sciences's PE Ratio (TTM) for today is calculated as:
Accustem Sciences's share price for today is $0.16.
Accustem Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.110.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Accustem Sciences EV-to-OCF Related Terms
Accustem Sciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Accustem Sciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Accustem Sciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accustem Sciences EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Accustem Sciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Accustem Sciences's EV-to-OCF falls into.
Accustem Sciences's current Enterprise Value is $2.62 Mil.
Accustem Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.21 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accustem Sciences (ACUT) has a EV-to-OCF of -2.18 as of Aug. 25, 2026. According to the industry distribution chart, Accustem Sciences ranks #817 out of 1409 companies in the Biotechnology industry, placing it in the top 58%.
Is Accustem Sciences' EV-to-OCF too high?
Accustem Sciences' current EV-to-OCF is -2.18. Based on the distribution chart, Accustem Sciences ranks #817 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Accustem Sciences has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Accustem Sciences' EV-to-OCF compare to SPRC and ONCO?
According to the Biotechnology industry distribution chart, Accustem Sciences ranks #817 out of 1409 companies for EV-to-OCF. This places Accustem Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Accustem Sciences's current EV-to-OCF is -2.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accustem Sciences stock overvalued right now?
Accustem Sciences (ACUT) has a current EV-to-OCF of -2.18. The current EV-to-OCF is -2.18. Accustem Sciences' overall GF Score™ is 29/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Accustem Sciences (ACUT), the current EV-to-OCF is -2.18 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accustem Sciences Inc is a clinical stage diagnostics company dedicated to improving quality of life and outcomes for the millions of people who are diagnosed with cancer each year. The company's product, StemPrintER, is a genomic platform for predicting distant recurrence risk in luminal, ER+/HER2-negative breast cancer patients. Additionally, It offers ancillary commodity testing to provide further insights. Validated in various retrospective cohorts, StemPrintER shows promise for oncology clinics. Revenue is generated through product commercialization and testing services.
29GF Score
Get the complete analysis for ACUT
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACUT has been successfully added to your 
